نتایج جستجو برای: 213bi

تعداد نتایج: 97  

2002
Joseph G. Jurcic Steven M. Larson George Sgouros Michael R. McDevitt Ronald D. Finn Chaitanya R. Divgi Åse M. Ballangrud Klaus A. Hamacher Dangshe Ma John L. Humm Martin W. Brechbiel Roger Molinet David A. Scheinberg

Unlike particle–emitting isotopes, emitters can selectively kill individual cancer cells with a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically targets myeloid leukemia cells and has activity against minimal disease. When labeled with the -emitters 131I and 90Y, HuM195 can eliminate large leukemic burdens in patients, but it produces prolonged myelosuppressi...

2002
Joseph G. Jurcic Steven M. Larson George Sgouros Michael R. McDevitt Ronald D. Finn Chaitanya R. Divgi Åse M. Ballangrud Klaus A. Hamacher Dangshe Ma John L. Humm Martin W. Brechbiel Roger Molinet David A. Scheinberg

Unlike particle–emitting isotopes, emitters can selectively kill individual cancer cells with a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically targets myeloid leukemia cells and has activity against minimal disease. When labeled with the -emitters 131I and 90Y, HuM195 can eliminate large leukemic burdens in patients, but it produces prolonged myelosuppressi...

Journal: :Journal of Medical Imaging and Radiation Sciences 2019

Journal: :Nuclear medicine and biology 2014
S Gouard A Pallardy J Gaschet A Faivre-Chauvet F Bruchertseifer A Morgenstern C Maurel E Matous F Kraeber-Bodéré F Davodeau M Chérel

INTRODUCTION Multiple myeloma (MM) is a B-cell malignancy of terminally differentiated plasma cells within the bone marrow. Despite intense research to develop new treatments, cure is almost never achieved. Alpha-radioimmunotherapy (RIT) has been shown to be effective in vivo in a MM model. In order to define where alpha-RIT stands in MM treatment, the aim of this study was to compare Melphalan...

Journal: :Molecules 2018
Ján Kozempel Olga Mokhodoeva Martin Vlk

This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitti...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید